Lupus & antiphospholipid syndrome
Association of mycophenolate and azathioprine use with cognitive function in systemic lupus
Authors' conclusion
AZA use was associated with significantly lower odds of SLE-CD, while MMF use was not.
Study context
- Population
- Consecutive adult SLE patients at a single healthcare center; ACR neuropsychological battery at 0, 6 and 12 months, scores compared with age- and sex-matched controls
- Participants
- 300 patients676 patient visits
- Exposure
- AZA and MMF use vs non-use, in relation to SLE cognitive dysfunction
- Outcome
- Cognitive dysfunction, defined as a z-score ≤−1.5 in two or more cognitive domains
Methodological detailssingle healthcare center, consecutive patients, mixed-effects logistic regression
- Single healthcare center
- Consecutive patients
- Mixed-effects logistic regression
Main finding
As reported in the abstract
Cognitive dysfunction (odds)
AZAOdds ratio (95% CI)P value
Per cumulative AZA dose (g/kg)
0.76(0.58–0.98)
P = 0.04Per year of AZA treatment
0.72(0.54–0.97)
P = 0.03Each row per its own increment, as printed
Observational data: associations, not effects.
Further findings
Cognitive dysfunction at baseline (prevalence)
- Met criteria for cognitive dysfunction (CD) at baseline
- 114 (38%)
Original publication
Association of mycophenolate and azathioprine use with cognitive function in systemic lupus. Rheumatology (Oxford). Published 22 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →